Shares in ReNeuron, a company working on stem-cell treatments for eye disease and strokes that is one-third owned by veteran investor Neil Woodford, rose more than 30 per cent on Tuesday, after it announced a licensing deal for its products to be developed and commercialised in China.
ReNeuron公司在周二宣布签署了一项授权协议、允许其产品在manbetx3.0 进行开发和商业化后，股价上涨逾30%。ReNeuron致力于开发治疗眼科疾病和中风的干细胞疗法，资深投资人尼尔•伍德福德(Neil Woodford)拥有该公司三分之一的股权。
您已阅读12%（406字），剩余88%（3056字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。